Innovative biomedical scientist specializing in CRISPR/Cas based genetic engineering with a focus on single nucleotide precision variant detection. Pioneered the development of the FnCas9 Editor Linked Uniform Detection Assay (FELUDA), a groundbreaking low-cost SARS-CoV-2 detection test, and the Rapid Variant Assay (RAY) for robust diagnosis of monogenic and infectious disorders. Currently exploring novel applications of CRISPR/Cas9 technology, including the concept of the CRISPR/Cas9 Utilizing Human Body Sticker (CRISticker) for visually identifying pathogenic variants in a sequencing-free manner. Excited about leveraging multiplexable assays to advance clinical research, disease genotyping, microbial infection surveillance, food safety, and industrial biotechnology.
eChai Ventures partners with select brands as their growth partner, helping them expand market reach, drive revenue growth, amplify brand visibility, and strengthen hiring efforts.
